Phase 2 trial of Translational approach to first line cHemoimmunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensive-Stage Small-Cell Lung CanceR (THOR trial)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514666-39-00

Acronym

IRST162.14

Enrollment

Registered

2024-07-16

Start date

2023-03-16

Completion date

Unknown

Last updated

2025-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

Brief summary

Progression-free Survival (PFS)

Detailed description

Objective response rate (ORR) and Immune-related objective response rate (irORR), Progression-free survival (PFS) at 6, 12 and 24 months, Overall Survival (OS), Safety profile

Interventions

DRUGCisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGETOPOSIDE TEVA 20 mg/ml

DRUGconcentrato per soluzione per infusione

DRUGOlaparib

DRUGCARBOPLATINO TEVA 10 mg/ml

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free Survival (PFS)	—

Secondary

Measure	Time frame
Objective response rate (ORR) and Immune-related objective response rate (irORR), Progression-free survival (PFS) at 6, 12 and 24 months, Overall Survival (OS), Safety profile	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026